Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market share.
However, Regeneron is constantly looking for its next billion-dollar medicine. And a recent deal it made with a smaller drugmaker helped it beef up its pipeline by acquiring an asset in the hottest therapeutic area right now: weight management. Is Regeneron stock a buy now?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Going up against a giant
Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per the terms of the agreement, Regeneron will pay an upfront amount of $80 million, with potential clinical and regulatory milestones of up to $1.93 billion, in addition to royalties on future sales.
HS-20094 mimics the action of two gut hormones: GLP-1 and GIP. The only approved medicine that does that is Zepbound, the weight loss therapy marketed by Eli Lilly. Zepbound has been a major hit, with incredibly fast-growing sales. Could HS-20094 become similarly successful? The fact that it's in the same class as Zepbound hardly guarantees so, but, according to Regeneron, the medicine has been tested in over 1,000 patients and has shown a potential similar to Zepbound.
It is currently undergoing a Phase 3 clinical trial for obesity and a Phase 2 study for diabetes. Results that are, in fact, on par with Zepbound might jolt Regeneron's share price. This isn't the only attempt by Regeneron to enter the weight loss market. The biotech company has been working on ways to address one drawback of anti-obesity medicines: muscle loss.
It recently announced top-line data in patients taking semaglutide (the active ingredient in the weight loss drug Wegovy) and trevogrumab, a medicine developed to address muscle atrophy. The trial showed that about 35% of weight loss due to semaglutide comes from lean muscle mass, but combining it with trevogrumab could help retain muscle mass while helping patients lose fat instead.
Does this make Regeneron a buy?
If HS-20094 becomes nearly as successful as Zepbound, the $80 million Regeneron paid -- and the $1.93 billion in milestones -- would represent quite the bargain. However, it is too early to celebrate. Despite Regeneron's confidence in this asset, many weight management candidates in the pharmaceutical industry have flopped. That's the nature of developing novel drugs. Most will never reach the market. But the fact that HS-20094 has reached late-stage studies is a good sign.
And at any rate, this move does not make Regeneron less attractive. There are, however, other reasons to buy the stock. Regeneron is mitigating Eylea-related losses with a new, high-definition (HD) version of the medicine, which will continue to attract patients away from the old version due to its more convenient dosing schedule. In the first quarter, total U.S. sales of Eylea and Eylea HD dropped by 26% year over year to $1.04 billion, but revenue from the latter increased by 54% year over year to $307 million.
Eylea HD should also earn some label expansions. Meanwhile, Regeneron's other growth driver is Dupixent, a medicine for eczema. It shares the rights to Dupixent with Sanofi. In the first quarter, Dupixent's sales came in at $3.67 billion, up 19% compared to the year-ago period. The therapy won an indication in treating COPD last year, so expect its revenue to continue moving in the right direction for a while. Regeneron's total sales in the first quarter dropped by 4% year over year to $3 billion.
However, as Eylea HD gains ground, including with new indications, Dupixent continues to make headway, and the biotech earns new products, including those in oncology, it should eventually start growing its sales again. Regeneron's work in weight management could, eventually, contribute to that. So, despite its recent headwinds, the stock still looks attractive.
Should you invest $1,000 in Regeneron Pharmaceuticals right now?
Before you buy stock in Regeneron Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!*
Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Foxconn Exports 97% of India-Made iPhones to U.S. to Avert China Tariffs
Apple's (AAPL) largest supplier Foxconn has ramped up exports of India-made iPhones to the U.S. to avoid the hefty tariffs on Chinese goods. According to a Reuters report citing official customs data, an average of 97% of iPhones produced in India were shipped to the U.S. between March and May. The data shows a stark jump in exports of Indian iPhones compared to the 50% monthly average recorded in 2024. India faces a baseline 10% tariff, while Trump has proposed a revised 55% tariff on Chinese imports following the U.S.-China trade deal. Confident Investing Starts Here: China has been the primary manufacturing hub for iPhones, with roughly 80% of U.S.-bound iPhones amounting to about 60 million units annually, originating from the mainland. The sharp redirection of orders to India highlights Apple's determination in skirting the hefty tariffs imposed by the U.S. government on Chinese goods. President Donald Trump aims to bolster America's manufacturing industries by implementing these tariffs, but large corporations are clearly finding alternative solutions to circumvent them. China Strengthens Its Strategy on India-Made iPhones Apple has manufacturing bases in several countries, including the Netherlands, Britain, and the Czech Republic. However, the company has recently grown increasingly dependent on India's manufacturing expertise. Despite several warnings from Trump to stop producing iPhones in India, CEO Tim Cook seems to be happily ignoring them. The company is said to have made special arrangements at the Chennai airport in Tamil Nadu state, its key iPhone export hub, to shorten customs clearance time from 30 hours to just six hours. Between March and May 2025, Foxconn exported iPhones worth $3.2 billion from India, with a majority destined for the U.S. market. In May alone, India exported $1 billion worth of iPhones to the U.S., following a record $1.3 billion in March. Notably, in the first five months of this year, Foxconn has already shipped India-made iPhones worth $4.4 billion to the U.S., compared to exports of $3.7 billion for the whole of 2024. In March, Apple sent six special chartered flights from India to the U.S., exporting the bulk of iPhones 13, 14, 16 and 16e models worth roughly $2 billion, just before Trump's global tariffs were expected to take effect. Apple's other Indian supplier, Tata Electronics, also exported 86% of its March and April iPhone production to the U.S., a significant increase from the 52% average recorded last year. Although India is promoting itself as a smartphone manufacturing hub, it still incurs high import duties on certain components, making manufacturing more expensive in India compared to Vietnam and Mexico. Is Apple a Good Stock to Buy Now? Analysts remain divided on Apple's long-term stock trajectory due to ongoing tariff-related uncertainty. On TipRanks, AAPL stock has a Moderate Buy consensus rating based on 16 Buys, nine Holds, and four Sell ratings. Also, the average Apple price target of $226.94 implies 13.9% upside potential from current levels. Year-to-date, AAPL stock has lost 20.3%. See more AAPL analyst ratings
Globe and Mail
5 hours ago
- Globe and Mail
Best Stock to Buy Right Now: Alibaba vs. Amazon
When it comes to tech stocks riding the artificial intelligence (AI) wave, both Amazon (NASDAQ: AMZN) and Alibaba (NYSE: BABA) are in strong positions. Each is leaning into AI to help drive growth for cloud computing and e-commerce businesses that both companies operate. Let's see which stock is the better buy. Alibaba: A turnaround with big AI ambitions Alibaba has been working hard to turn around its core e-commerce business. It has been investing heavily in Tmall and Taobao to reaccelerate gross merchandise volume (GMV) growth and is now beginning to monetize that higher GMV more effectively through a small software fee and its AI-powered marketing tool, Quanzhantui. Last quarter, its e-commerce revenue rose 9% year over year, while third-party revenue jumped 12%. More importantly, segment earnings before interest, taxes, and amortization (EBITA) climbed 8%. At the same time, Alibaba is seeing strong momentum in its cloud computing business. Its Cloud Intelligence segment revenue increased by 18% year over year last quarter, as AI-related revenue more than doubled for the seventh consecutive quarter. Impressively, its adjusted EBITA surged by 69%, demonstrating the segment's strong operating leverage. Alibaba's AI push is being driven by its Qwen series of models. In addition to a strong foundation model, it's rolled out versions specifically built for tasks like coding and math. Its latest release, Qwen3, is a new class of "hybrid reasoning" models that combine traditional large language model capabilities with more advanced, dynamic reasoning. Meanwhile, Alibaba scored a huge win earlier this year when Apple chose its models to power Apple Intelligence in China, although the deal has been delayed by Chinese regulators. Nonetheless, it's a clear sign that Alibaba's AI efforts are gaining traction despite the U.S. chip export ban. In addition to its core e-commerce and cloud computing businesses, Alibaba also has a big opportunity with its international commerce segment (AIDC), which includes AliExpress and Turkey-based Trendyol. This segment grew revenue by 22% last quarter, and management expects it to turn profitable within the next year. Flipping AIDC into the black could be a major tailwind for earnings growth going forward. Despite its recent rally, Alibaba still looks incredibly cheap. The stock trades at around 12 times forward earnings, with nearly $20 billion in net cash and another $57 billion in equity investments on its balance sheet. If sentiment around Chinese equities continues to improve, there could be meaningful upside in the stock from here. Amazon: An efficient growth machine Amazon is less of a turnaround story and more of a manual on relentless operational execution. It's already a $2 trillion market cap behemoth, but it's still finding ways to increase revenue growth and drive margins higher. Its cloud computing unit, Amazon Web Services (AWS), remains its crown jewel. Revenue jumped 17% year over year last quarter to $29.3 billion, while operating income grew even faster, up 23%. AI is a big reason for this. Amazon is seeing strong demand for its Bedrock and SageMaker solutions, which help customers build, fine-tune, and deploy AI models. At the same time, it has also developed its own custom AI chips, which can boost performance and use less energy. This helps reduce costs, which could be a key long-term differentiator. However, Amazon isn't just leaning into AI to drive growth at AWS; it's using AI across its entire ecosystem to drive efficiencies. In its warehouses, Amazon is developing AI-powered robots that can do everything from lifting heavy boxes to spotting damaged goods. On the logistics side, it is using AI to optimize delivery routes, navigate large apartment complexes, lower fuel costs, and improve customer satisfaction. In e-commerce, Amazon is using AI to help third-party merchants create stronger, more effective product listings, while on the advertising side, it's using AI to drive improved campaign performance through better targeting and more compelling ad content. All of this is leading to improved operating leverage in the e-commerce business. In Q1, its North American revenue rose 8%, while operating income jumped 16%. However, given that Amazon is still in the early innings of rolling out these AI initiatives, the best is yet to come. From a valuation perspective, Amazon trades at a forward P/E of 34.5 times, which is obviously much higher than Alibaba. Which stock is the better buy? Both Alibaba and Amazon are e-commerce leaders with strong, growing cloud computing businesses. Both have also embraced AI and are looking to be leaders in the field. In my view, Alibaba has more potential upside. It appears to be successfully turning around its e-commerce business, is an AI leader in China domestically, and has a big potential earnings driver with its AIDC business. Most importantly, it trades at a deep discount to Amazon. That said, Amazon is the safer play. Alibaba faces more risks from geopolitical tensions, tougher domestic competition, and a murky regulatory environment in China. Amazon, meanwhile, is a proven compounder that has shown time and again that it's willing to invest heavily in order to win big. While it faces typical retailer risks related to consumer spending, this is a company that I have little doubt will be a long-term AI winner. As such, for investors looking for more potential upside, Alibaba is the clear choice. However, from a risk-reward perspective, investors can't go wrong with Amazon. Should you invest $1,000 in Alibaba Group right now? Before you buy stock in Alibaba Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alibaba Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Apple. The Motley Fool recommends Alibaba Group. The Motley Fool has a disclosure policy.
Globe and Mail
10 hours ago
- Globe and Mail
Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive?
[content-module:CompanyOverview|OTCMKTS:NTDOY] However, investors who bought NTDOY stock earlier this year may easily have enough profits to cover the premium price. The stock is up 43% in 2025 and is trading near its all-time high. A run-up like that leads to concerns that there's not much upside left. Events like the Switch 2 launch can be a 'sell the news' event. NTDOY stock is up just 1.3% in a volatile week of trading since the Switch 2 launch. However, analysts give NTDOY stock a consensus price target of $25.60, which would be a 22% upside from the stock's closing price on June 10. What do investors need to know about the opportunity in Nintendo stock? Nintendo Is Affirming Its Premium Position By many accounts, Nintendo saved the video game industry in the mid-1980s. At that time, the company established itself as offering premium value, and it's never deviated from that. Nintendo is well-known for prioritizing software development. The company has a long-standing policy of limiting the number of games its developers can make, so the focus is on quality rather than quantity. From 2019 through 2023, about 80% of the company's software revenue came from its first-party games. In fact, it's never had a gaming console priced higher than $300. Even at $450, the Switch 2 is priced less than the Sony PlayStation of 20 years ago. Consumers have had to wait for the Switch update for eight years, so they may accept that price hike. However, the price of video games made for the Switch is also increasing. Mario Kart, the signature game for the device, will be $80. That's significantly higher than the previous $60 price point from the prior version. Some analysts believe that tariffs played a role. Nintendo is denying the claims, and there's some evidence that on an inflation-adjusted basis, the new pricing is still very favorable. However, the launch is coming at a time when many consumers are stretched and stressed. An Outlier in a Weak Sector Consumer discretionary stocks continue to be hit or miss for investors. The Consumer Discretionary Select Sector SPDR Fund (NYSEARCA: XLY) is down about 3% in 2025. Some of the top holdings in the fund including Tesla Inc. (NASDAQ: TSLA), Lululemon Athletica Inc. (NASDAQ: LULU), and more recently McDonald's Corp. (NYSE: MCD) have been among the market laggards. This was supposed to be a great year for these stocks. The expectation was that inflation and interest rates would come down, and consumers would take care of the rest. But during the first half of 2025, that forecast hasn't materialized yet. The rate of inflation has decreased, but not enough to prompt the Federal Reserve to take action. Additionally, the potential impact of tariffs is holding consumer sentiment back. [content-module:TradingView|OTCMKTS:NTDOY] Fundamentals Are Bearish, But Technicals Suggest Bullish Momentum A price-to-earnings (P/E) ratio of around 46x puts Nintendo above its historical averages. The same is true of the stock's price-to-sales (P/S) ratio and its price-to-book (P/B) ratio. Nevertheless, its most recent earnings report in May didn't include any of the benefits from the Switch 2 launch. It's fair to say that some of that is priced into the stock already. The bottom line is that if the company doesn't meet its goals for the Switch 2 launch, there could be significant value compression. But in the near term, the NTDOY stock chart looks slightly bullish. After moving to an all-time high, the stock is finding resistance, which is just shy of $21. However, the moving average convergence divergence (MACD) has been swinging from bullish to bearish and appears to be ready to swing bullish again. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...
